Prof. Frank McCormick, Ph.D., F.R.S. D.Sc. (Hon), has been Scientific Founder of Avidity Biosciences LLC since 2012. Prof. McCormick serves as a Scientific Advisor of Kura Oncology, Inc. Prof. McCormick has been a Scientific Founder of Avidity NanoMedicines LLC since 2012. He serves as an Ad-Hoc Advisor of PrognosDx Health, Inc. He serves as an Advisor at AGLAIA BioMedical Ventures B.V. He is a Co-Founder of DNAtriX, Inc. He serves as a Scientific Advisor at Onyx Pharmaceuticals, Inc., Exelixis Inc., the Jackson Laboratory, the National Cancer Institute and Massachusetts General Hospital, Lawrence. He has been a Senior Advisor of Research and Development Organization, since October 30, 2003. Prof. McCormick has been an Associate Dean of School of Medicine of UCSF, since 1997. He founded Onyx Pharmaceuticals in 1992 and served as the Chief Scientific Officer from 1992 to 1996. He served as a Medical Advisor at DNA Direct, Inc. He served as a Vice President of Therapeutic Research at Chiron, Corp. from 1991 to 1992. He served as a Vice President of Discovery Research at Cetus Oncology Corporation from 1981 to 1990, Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991. He served variety of Senior Scientist positions at several biotechnology companies. Prof. McCormick serves as Chairman of Scientific Advisory Board of Kyras Therapeutics Inc. He has been the David A. Wood Chair of Tumor Biology and Cancer Research in the Department of Microbiology and Immunology at University of California since 1998. He served as the President of the Board of Director's of American Association for Cancer Research (AACR) from April 2, 2012 to April 2013. He served as the Chairman and Member of the Scientific Advisory Board at NexGenix Pharmaceuticals Holdings, Inc. He serves as a Director of the University of California, San Francisco (UCSF) Comprehensive Cancer Center. He serves as a Director of Onyx Pharmaceuticals, Inc. and DNAtriX, Inc. He serves as a Member of Advisory Board of DiaCarta Inc. Prof. McCormick has been a Director of Aduro BioTech, Inc. since 2010 and serves as its Member of Scientific Advisory Board. He serves as a Member of Scientific Advisory Board and Member of Board of Managers at Avidity Biosciences LLC. He serves as a Director and Member of Scientific & Clinical Advisory Board at BiPar Sciences, Inc. He serves as Member of Scientific Advisory Board of Portola Pharmaceuticals, Inc., Pancreatic Cancer Action Network, Inc., SillaJen Biotherapeutics, Inc., ORCA Therapeutics B.V., PMV Pharmaceuticals, Inc., Iconix Pharmaceuticals, Inc., Sagres Discovery, Inc. and KineMatik Ltd. He has been a Member of Scientific Advisory Board of Dicerna Pharmaceuticals, Inc. since October 2008. He has been Member of Advisory Board at Fluidigm Corporation since December 11, 2006. He serves as Member of Scientific Advisory Board of Innovent Biologics, Inc. and Caris Life Sciences, Inc. He serves as a Member of the UCSF Biomedical Sciences Program and the Herbert Boyer Program in Biological Sciences. He is on the Advisory Boards of Memorial Sloane Kettering, Dana Farber Cancer Center, the Canary Foundation, the University of Wisconsin Comprehensive Cancer Center and the University of Texas, Southwestern Advisory Board. He serves on the Editorial Board of some of the most prestigious international cancer publications and serves as a Board Member or Advisor to multiple cancer research organizations. He served as a Member of Scientific Advisory Board at OncoCyte Corporation. He served as a Member of Scientific Advisory Board of Aglaia Biomedical Ventures B.V. He served as a Member of Scientific Advisory Board at Iconix Biosciences, Inc. He served as a Director of American Association For Cancer Research. He served as a Director of Exelixis, Inc. from July 31, 2003 to May 28, 2014 and served as its Member of the Scientific Advisory Board. He served as a Director of UCSF Helen Diller Family Comprehensive Cancer Center from March 17, 2014 to December 31, 2014. He serves as a Professor of Tumor Biology and Cancer Research, Department of Microbiology and Immunology at University of California-San Francisco. He is an Emiritus Professor of the University of California, San Francisco. He is Professor Emeritus of the UCSF Helen Diller Family Comprehensive Cancer Center. He is the E. Dixon Heise distinguished Professor in Oncology. He serves as RAS National Program Advisor and Member of the National Academy of Sciences. He has authored more than 285 scientific publications, edited five books and holds 21 patents. He has received numerous awards in recognition of his contributions to the field of cancer research. In 2002, he received the prestigious 42nd AACR G.H.A. Clowes Memorial Award for his seminal contribution to studies of the structure and function of oncogenes, which has led to a myriad of novel therapeutic approaches. He has been a Fellow of the Royal Society, since 1996. He was a Post Doctoral Fellow with Dr. Allen Smith at the Imperial Cancer Research Fund in London, England and with Professor Seymour S. Cohen at the State University of New York at Stony Brook. He holds the David A. Wood Chairman of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. He is an expert on tumor suppressor genes and the RAS pathway. He is a distinguished Cancer Researcher focused on signal transduction pathways in cancer cells and ways of treating cancer based on these pathways. He is a Molecular Biologist and nationally recognized Research Scientist in Cancer Biology. Prof. McCormick is also the 2012-2013 President of the American Association for Cancer Research (AACR) multiple disease areas. He has a Ph.D. in Biochemistry from the University of Cambridge, England in 1975 and a B.S. in Biochemistry from the University of Birmingham, England in 1972.

 Oncology